Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

This study is testing a drug called ruxolitinib in patients with T-cell or NK-cell lymphoma (types of immune system cancers) that have come back or stopped responding to previous treatments. **You may be eligible if...** - You have been confirmed to have a T-cell or NK-cell lymphoma at the study site - Your cancer has relapsed or stopped responding to at least one prior treatment (with some exceptions for specific subtypes) - You are 18 years of age or older - Your general health is good enough to participate (ECOG score 0–2) - Your cancer can be measured on imaging or skin exams - Your organ function (blood, liver, kidneys) meets the required levels **You may NOT be eligible if...** - You have had more than 3 prior lines of treatment (depending on the subtype) - You have uncontrolled infection or serious other illnesses - You are pregnant or breastfeeding - You are taking medications that could interact with ruxolitinib Talk to your doctor to see if this trial is right for you.